Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilmanocept vs Nanocolloid for Sentinel Node Detection in Breast Cancer
NCT04487912Phase 4Withdrawn
- Sponsor
- Ghent University Hospital
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of technetium tc 99m tilmanocept in breast cancer, sponsored by Ghent University Hospital. Planned start Nov 2020; status: withdrawn.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04487912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487912.